GlassScriptPhysician profile
Sunil K Jagadesh
NPI 1932320066
$4,380.03
in general payments reported to CMS, 2019-2025
32 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $105 · 2021: $183 · 2022: $563 · 2023: $1,004 · 2024: $978 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.08 |
| Education | $138.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $432.41 | 2019-2025 | Veltassa |
| Amgen INC. | $425.17 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $405.09 | 2021-2025 | |
| Travere Therapeutics, INC. | $367.25 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $360.92 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $343.44 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $296.99 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $257.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.39 | 2019-2025 | Farxiga |
| Ani Pharmaceuticals, INC. | $185.04 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.08 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $145.83 | 2023-2025 | Velphoro, Velphoro, Korsuva |
| Abbott Laboratories | $145.06 | 2025 | Cardiomems |
| Alexion Pharmaceuticals, INC. | $126.18 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $112.97 | 2023-2025 | Benlysta, Shingrix, Arexvy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $50.24 | 2023-2025 | |
| Novo Nordisk INC | $41.09 | 2025 | Wegovy |
| Veloxis Pharmaceuticals, INC. | $29.53 | 2025 | Envarsus |
| Kyowa Kirin, INC. | $28.73 | 2024 | Crysvita |
| Cormedix INC. | $28.60 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $26.99 | 2025 | Empaveli |
| Lilly USA, LLC | $24.30 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $22.14 | 2025 | Injectafer |
| Ardelyx, INC. | $22.01 | 2025 | Ibsrela |
| Akebia Therapeutics INC | $21.87 | 2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $18.34 | 2025 | Lupkynis |
| Mozarc Medical US LLC | $17.25 | 2024 | Palindrome |
| Nxstage Medical, INC. | $16.28 | 2024 | |
| Horizon Therapeutics Plc | $15.44 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $15.28 | 2025 | Keveyis |
| Janssen Pharmaceuticals, INC | $14.61 | 2019 | |
| Electromed, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Jagadesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.